-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Adefovir-[d4]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1190021-70-5.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 1190021-70-5 |
| Description | Adefovir-[d4] is the labelled analogue of Adefovir, which is an antiviral drug used for the treatment of infections caused by hepatitis B virus. |
Product Information
| Synonyms | Adefovir D4; P-[[2-(6-Amino-9H-purin-9-yl-d4)ethoxy]methyl]phosphonic Acid; 9-(2-Phosphonylmethoxyethyl)adenine-d4; [[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosponic Acid-d4; GS 0393-d4; PMEA-d4 |
| IUPAC Name | [2-(6-aminopurin-9-yl)-1,1,2,2-tetradeuterioethoxy]methylphosphonic acid |
| Molecular Weight | 277.21 |
| Molecular Formula | C8H8D4N5O4P |
| Canonical SMILES | C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N |
| InChI | InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)/i1D2,2D2 |
| InChIKey | SUPKOOSCJHTBAH-LNLMKGTHSA-N |
| Boiling Point | 632.5±65.0 °C at 760 mmHg |
| Melting Point | >250°C (dec.) |
| Flash Point | 336.3±34.3 °C |
| Purity | ≥98%; ≥99% atom D |
| Density | 1.9±0.1 g/cm3 |
| Solubility | Soluble in DMSO (Slightly) |
| Appearance | White to Off-white Solid |
| Storage | Store at -20°C under inert atmosphere |
| Complexity | 327 |
| Exact Mass | 277.087799 |
| Index Of Refraction | 1.769 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | HBV; Reverse Transcriptase |
| Vapor Pressure | 0.0±2.0 mmHg at 25°C |
| XLogP3-AA | -2 |
